December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

61.75 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗
The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. 
Via Stocktwits
News headline image
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? ↗
B. Lynne Parshall sold $323,650 worth of Cytokinetics shares in November. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What Does the Market Think About Cytokinetics Inc? ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Cytokinetics (CYTK) Q3 2025 Earnings Transcript ↗
Cytokinetics (CYTK) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Tuesday's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? ↗
Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten. 
Via Benzinga
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Tuesday's pre-market session: top gainers and losers ↗
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease ↗
Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers. 
Via Investor's Business Daily
News headline image
Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy — Here's Where He's Investing Instead ↗
A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments. 
Via Benzinga
News headline image
CYTK Earnings Jump 3,065% ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months ↗
FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review. 
Via Benzinga
News headline image
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach ↗
FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.